Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Healius Limited ( (AU:HLS) ).
Healius Limited has announced the unconditional sale of its Lumus Imaging division to Affinity Equity Partners, with the completion date set for May 1, 2025. This strategic move, following the fulfillment of all conditions including regulatory approvals, is expected to impact Healius’s operations by allowing it to focus more on its core diagnostics services, potentially enhancing its market positioning and value for stakeholders.
More about Healius Limited
For over 30 years, Healius Limited has been a leading healthcare company in Australia, focusing on providing quality, affordable, and accessible healthcare. The company operates two core diagnostics businesses: pathology and imaging, offering specialty diagnostic services through a network of centers and over 10,500 employees across the country.
YTD Price Performance: -9.15%
Average Trading Volume: 1,194
Technical Sentiment Signal: Strong Buy
Current Market Cap: €561.8M
Learn more about HLS stock on TipRanks’ Stock Analysis page.